4/24/2015. Urgent, STAT, Super STAT, ASAP! Achieving timely lab testing for the Emergency Department. Learning Objectives.



Similar documents
TIME LOST IS BRAIN LOST. TARGET: STROKE CAMPAIGN MANUAL

Level III Stroke Center Data Collection Requirements

TPA, STROKE, & TELEMEDICINE. Improving utilization and improving outcomes in a constantly evolving field

Developing a Dynamic Team Approach to Stroke Care. Emergency Medical Services 2015

New Treatments for Stroke Prevention in Atrial Fibrillation. John C. Andrefsky, MD, FAHA NEOMED Internal Medicine Review course May 5 th, 2013

DVT/PE Management with Rivaroxaban (Xarelto)

Stroke Systems of Care

Appendix L: HQO Year 1 Implementation Priorities

EMS Management of Stroke. Deaver Shattuck, M.D. Brian Wiseman, M.D. Keith Woodward, M.D.

Therapeutic Management Options for. Acute Ischemic Stroke Anna Rosenbaum, MD

Stroke/VTE Quality Measure Build for Meaningful Use Stage 1

LAP Audioconference How to Prepare and Comply with Your Quality Management Plan* February 18, 2009

A Collaborative Effort to Improve Emergency Stroke Care: Mobile Stroke Unit

Managing POCT: Trying to Control Testing in an Out-of-Control Environment. William Clarke, PhD, MBA, DABCC Johns Hopkins School of Medicine 3/24/11

Dabigatran (Pradaxa) Guidelines

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Acute Myocardial Infarction (the formulary thrombolytic for AMI at AAMC is TNK, please see the TNK monograph in this manual for information)

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

STARTING, SWITCHING OR STOPPING NEW ORAL ANTICOAGULANTS: A Practical Approach

Primary Stroke Certification

2009 LAP Audioconference Series. How to Prepare and Comply with Your Quality Management Plan

Laboratory Quality Metrics

The author has no disclosures

PHYSICIAN SIGNATURE DATE TIME DRUG ALLERGIES WT: KG

King County EMS Stroke Quality Improvement Program

Going Beyond Laboratory Automation: Do Less Accomplish More. Swedish Covenant Hospital

Approved: Acute Stroke Ready Hospital Advanced Certification Program

Bleeding disorders or haemorrhagic diatheses are a group of disorders characterised by defective haemostasis with abnormal bleeding.

Novel Anticoagulation Agents DISCLOSURES. Objectives ATRIAL FIBRILLATION TRIALS. NOAC Comparison 6/12/2015

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

Samsung POINT OF CARE Systems - Cardiac/Acute Care Biomarkers LABGEO IB Clinical Chemistry Analytes LABGEO PT

REMINDER: Please ensure all stroke and TIA patients admitted to hospital are designated as "Stroke Service" in Cerner.

PoCT Troponin Improving Patient Outcomes in Rural and Remote Settings

A Patient s Guide to Antithrombotic Therapy in Atrial Fibrillation

Quality Control of the Future: Risk Management and Individual Quality Control Plans (IQCPs)

Critical Bleeding Reversal Protocol

Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC November 2, 2011

All patients presenting to the Emergency Department with symptoms suggestive of

Lean Strategies Used to Optimize Automation. Why Lean Six Sigma? Laboratory Goals. Decreased TAT. Accurate Results. LEAN Goals.

Point-of-care (POC) versus central laboratory instrumentation for monitoring oral anticoagulation

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

NnEeWw DdEeVvEeLlOoPpMmEeNnTtSs IiıNn OoRrAaLl AaNnTtIiıCcOoAaGgUuLlAaTtIiıOoNn AaNnDd RrEeVvEeRrSsAaLl

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

AR SAVES. INTRODUCTION AND UPDATES FOR ER PHYSICIANS. Nicolas Bianchi, MD. August 23 rd, 2012.

Patient Safety and the Laboratory

Crittenton Hospital Medical Center Primary Stroke Center. Cesar D.Hidalgo, MD. Stroke Program Medical Director

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

2015 Data Validation Strategy

CLINICAL QUALITY MEASURES FINALIZED FOR ELIGIBLE HOSPITALS AND CRITICAL ACCESS HOSPITALS BEGINNING WITH FY 2014

COMMISSION ON LABORATORY ACCREDITATION. Laboratory Accreditation Program LABORATORY GENERAL CHECKLIST

To aid practitioners in prescribing unfractionated heparin and low-molecular-weight heparins to patients.

Medicina di laboratorio in urgenza/emergenza I perché dell integrazione routine-urgenze

Contents. Abstract... i. Committee Membership... iii. Foreword... vii. 1 Scope Introduction Standard Precautions...

HL7 Role-based Access Control (RBAC) Role Engineering Process - Applied Example. Version 1.1. HL7 Security Technical Committee

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

How To Manage An Anticoagulant

Prof. Dr. med. Roland Bingisser Head of Clinical Emergency Medicine University Hospital Basel. making?

ACUTE STROKE PATHWAY

9/5/14. Objectives. Atrial Fibrillation (AF)

Interpretation of Laboratory Values

Bringing Big Data to Quality Improvement in the Sentinel Stroke National Audit Programme (SSNAP)

Preparing Your Hospital for Primary Stroke Certification Authors: Wendy J. Smith, BS, MA, RES, RCEP, RN Claranne Mathiesen, MSN, RN, CNRN

ADMINISTRATIVE MANUAL Policy and Procedure

PROTOCOL TITLE: Ambulatory Initiation and Management of Warfarin for Adults

Lupus anticoagulant Pocket card

Analytical Specifications RIVAROXABAN

How to Maximize Your Lab s Value to Cardiac Care Sammie Sue Hendrix Laboratory Director Citizens Medical Center, Victoria Texas

A list of FDA-approved testosterone products can be found by searching for testosterone at

STATEMENT OF STANDARD

Code Stroke: Early Recognition and Emergency Management of the Acute Stroke Patient

Building an Emergency Response to Acute Stroke

USING CLSI GUIDELINES TO PERFORM METHOD EVALUATION STUDIES IN YOUR LABORATORY

AHA/ASA Ischemic Stroke Performance Measures

USE AND INTERPRETATION OF LABORATORY COAGULATION TESTS IN PATIENTS WHO ARE RECEIVING A NEW ORAL ANTICOAGULANT (DABIGATRAN, RIVAROXABAN, APIXABAN)

Sutter Health Support Services Shared Laboratory Position Description. Incumbent: Laboratory Date: October 23, 2006 Written By: Michele Leonard

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies

Anticoagulation before and after cardioversion; which and for how long

New Anticoagulants: What to Use What to Avoid

Annex 15-A: W. Edwards Deming 14 Points for Quality

The management of cerebral hemorrhagic complications during anticoagulant therapy

Content Sheet 5-1: Overview of Sample Management

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

Anticoagulation For Atrial Fibrillation

Embedding Point of Care monitoring (ROTEM) in daily practice

New Oral Anticoagulant Drugs What monitoring if any is required?

Overview of the TJC/CMS VTE Core Measures

convey the clinical quality measure's title, number, owner/developer and contact

Best Practices for Maintaining Quality in Molecular Diagnostics Gyorgy Abel, MD, PhD

Long term anticoagulant therapy in patients with atrial fibrillation at high risk of stroke: a new scenario after RE-LY trial

Planning: Patient Goals and Expected Outcomes The patient will: Remain free of unusual bleeding Maintain effective tissue perfusion Implementation

Transcription:

Urgent, STAT, Super STAT, ASAP! Achieving timely lab testing for the Emergency Department Nichole Korpi-Steiner, PhD, DABCC, FACB University of North Carolina Chapel Hill, NC Learning Objectives Describe the clinical need and TAT requirements for lab results in the assessment of acute ischemic stroke patients Define test TAT metrics used to assess lab quality performance Discuss different strategies for achieving timely testing for the emergency department Case Study 16:00 80 yr female fell in her living room. Grandson found her displaying symptoms of right facial droop and slurred speech http://www.strokeassociation.org/strokeorg/professionals/target Stroke; Accessed 03/12/15 1

Case Study: CODE STROKE 16:00 80 yr female fell in her living room. Grandson found her displaying symptoms of right facial droop and slurred speech EMS 17:20 ED CODE STROKE Acute Ischemic Stroke Acute ischemic stroke is 4 th leading cause of death in USA Standard Care Treatment: Intravenous tissue plasminogen activator (tpa) o Only FDA-approved pharmacological therapy for treatment of patients with acute ischemic stroke o Associated with odds of favorable outcome (OR 1.9; 95% CI, 1.2-2.9) when administered within 3 h of symptom onset European Medicines Agency expanded use to 4.5 h US FDA limits use to within 3 h of symptom onset Rapid patient evaluation, diagnosis & treatment of ischemic stroke in the ED is paramount o Narrow treatment window for acute ischemic stroke Jauch et al. Stroke. 2013; 44:870 947. Tissue Plasminogen Activator (tpa) Serine protease that activates fibrinolytic pathway Plasminogen tpa Plasmin Fibrin Fibrin degradation products Major risk is intracranial hemorrhage, which may be fatal Jauch et al. Stroke. 2013; 44:870 947. 2

Importance of Time in tpa Treatment From the GWTG-Stroke data (2003-2009), among 25,504 acute ischemic stroke patients treated with IV tpa within 3 hours of symptom onset at 1082 hospital sites: o Door-to-needle times 60 minutes was associated with lower odds of in-hospital mortality (adjusted OR, 0.78; 95% CI, 0.69 to 0.90; P<0.0003) o For every 15 min reduction in door-to-needle time, there was a 5% lower odds of in-hospital mortality (adjusted OR, 0.95; 95% CI, 0.92-0.98; P=0.0007) AHA/ASA Goal: Door-to-needle time < 60 min for at least 80% of ischemic stroke patients Fonarow et al. Circulation. 2011;123:750 758 Jauch et al. Stroke. 2013; 44:870 947 2013 AHA/ASA Guideline for the Early Management of Patients with Acute Ischemic Stroke Patient Assessment: Patient history Lab findings Neurological assessment Brain imaging Cardiovascular assessment Jauch et al. Stroke. 2013; 44:870 947. 2013 AHA/ASA Guideline for the Early Management of Patients with Acute Ischemic Stroke Because time is critical, a limited number of essential diagnostic tests are recommended: Labs to consider IV tpa Exclusion Criteria Glucose < 50 mg/dl (2.7 mmol/l) Complete blood count (CBC) Platelets < 100,000/mm 3 (< 100 x 10 9 /L) Prothrombin time (PT) > 15 sec International normalized ratio (INR) > 1.7 Activated partial thromboplastin time > Upper limit of normal (aptt) Troponin Creatinine Electrolytes Jauch et al. Stroke. 2013; 44:870 947. 3

15:30 Case Study: CODE STROKE Time of symptom onset patient last known normal 80 yr female fell in her living room. Grandson found her 16:00 displaying symptoms of right facial droop and slurred speech EMS 17:20 ED CODE STROKE Lab tests ordered, collected & sent to lab Patient history Neurological assessment CT scan EKG Stroke 17 yr ago, Type II diabetes, atrial fibrillation (coumadin) National Institute of Health Stroke Scale = 5 Negative for intracranial hemorrhage Atrial fibrillation, 77 bpm 15:30 Case Study: CODE STROKE Time of symptom onset patient last known normal 80 yr female fell in her living room. Grandson found her 16:00 displaying symptoms of right facial droop and slurred speech EMS 17:20 ED CODE STROKE Lab tests ordered, collected & sent to lab 18:08 Lab test Patient results Reference Range Glucose 96 (5.3) 69 175 mg/dl (3.8 9.7 mmol/l) Platelets 283 x 10 9 150 440 x 10 9 /L PT 14.4 9.7 12.1 sec INR 1.3 aptt 28.7 26.2 36.9 sec Troponin <0.034 (< 34) < 0.034 ng/ml (< 34 ng/l) 15:30 Case Study: CODE STROKE Time of symptom onset patient last known normal 80 yr female fell in her living room. Grandson found her 16:00 displaying symptoms of right facial droop and slurred speech EMS 17:20 ED CODE STROKE Lab tests ordered, collected & sent to lab 18:08 18:30 Patient lab test results available; Lab TAT: 48 min Informed consent for fibrinolytic therapy IV tpa administered to patient Door to needle time: 70 min Symptom onset to IV tpa TAT: 3 h 4

Why is Test Turnaround Time (TAT) Important? Laboratory support for patient-centered care Operational efficiency Customer (Physician/ Nurse/ Patient) satisfaction TAT is a key performance indicator of laboratory services o One of the most noticeable signs of laboratory service Used by many clinicians to judge the quality of the lab Delays in lab test TAT is a major source of complaints from laboratory services users Customer Satisfaction Surveys Customer (e.g. Physician) satisfaction surveys are used as a surrogate indicator for the quality of lab services o Important component of lab quality assurance program and a quality indicator accepted by accreditation organizations (e.g. 2014 CAP, GEN.20316) 2009 CAP Q Probe study 4392 Physician responses o Limitations Subjective and may not accurately reflect views of patients and other stakeholders Jones et al. Arch Pathol Lab Med. 2009;133:38 43 Clinical and Lab Perceptions of TAT Expectations Median = 37.5 min n= 1352 physicians Median = 60 min n= 119 labs Median = 91 min n= 119 labs (TAT = order to report) Lab services and test users should work together to develop and agree on TAT goals that meet the needs of the medical staff and can be reasonably achieved CAP Q probes study; Novis et al. Arch Pathol Lab Med. 2004;128:158 164 5

Definition of TAT Institutions should define TAT and what you are measuring o Consider the total testing process and workflow o Defining TAT should be a multi-disciplinary cooperative effort Patient arrival Order Preanalytic Analytic Collection Transport Receipt in lab Processing Analysis Lab TAT Total TAT Postanalytic Result reporting Clinical decision Defining TAT Goals Seek resources for guidance 2013 AHA/ASA Guideline Door to needle TAT 60 min Guidelines (Door to tpa administration) Accreditation Standards TAT Goal External QI Programs E.g. CAP Q Probes Institution Medical Staff Comprehensive Stroke Center (CSC) Standards CSC Certification requires monitoring key quality stroke care metrics DSPM.3, EP2b: Documentation indicates ability to complete and report lab tests in < 45 minutes from being ordered 2014 The Joint Commission Comprehensive Stroke Center Standards 6

STAT Testing Approaches for the ED In general, Stat testing in central laboratory Satellite lab testing in the ED Point of Care Testing One size does not fit all, and will vary between institutions Improving ED STAT Test TAT Performed in the Central Laboratory Flow diagrams of patient arrival (door) to specimen collection Median door to order TAT: 54 min Median door to order TAT: 11 min Preanalytical clinical workflow is an important TAT consideration Multidisciplinary collaboration and teamwork between the ED and laboratory were central to the success of reducing troponin (door to result report) TAT to < 60 min Boelstler et al. Clin Biochem. 2015; 48:308 312 Specimen Type Consideration for Rapid TAT Serum specimens o With silica clot activator recommend 30 min for blood clotting o With thrombin clot activator recommend 5 min for blood clotting o Blood from patients receiving anticoagulant therapy may take longer to clot Plasma or anticoagulated whole blood specimens can mitigate blood clotting time issues o Requires adequate volume filling and mixing with anticoagulant Differences in test results between plasma, serum and whole blood have been reported need to validate specimen types o 2010 CLSI GP34-A Validation and Verification of Tubes for Venous and Capillary Blood Specimen Collection; Approved Guideline Kocijancic et al. Biochemia Medica. 2014;24(3):368 75 7

Improving ED STAT Test TAT Performed in the Central Laboratory Median ctni TAT (order to report) 52.8 min 41.8 min 30.6 min Changes in lab specimen management, including the use of a pneumatic tube and computerized order management, resulted in a progressive decrease in lab TAT for ED Guss et al. Ann Emerg Med. 2008; 51:181 185. Improving STAT Test TAT Using a Satellite Laboratory in the ED Central lab located in different building 300 m from ED o Dedicated couriers transported the specimens o Pneumatic tube system considered but found to be costly ED Central Lab Implemented satellite lab (lab analyzers) in the ED Median Collect to receipt TAT Median Collect to report TAT Central Lab 22 min 67 min Satellite Lab 1 min 35 min Dhatt et al. Clin Chem Lab Med 2008;46:1464 7. Considerations for Improving STAT Test TAT Preanalytical (Sample receipt and processing) o Barcode-labeled specimens o Different colored labels for STAT specimens o Designated pneumatic tube / receipt station for STAT specimens o Designated STAT processing area with STAT centrifuge o Front-end automation for automated receipt, centrifugation and aliquoting Analytical o Instrument selection - test analysis time and performance o Instrument redundancy o Auto-repeat, -dilutions, -reflex testing o Auto-verification Post-analytical o Interfaced result reporting to electronic medical record Staffing Workflow 8

Improving STAT Test TAT Using Point of Care Testing (POCT) in the ED POCT is lab testing performed close to the site of patient care, typically by non-laboratory personnel o Can work well with clinical patient flow o Typically no sample transport or processing required o Results immediately available to caregiver Implemented POC troponin testing for chest pain patients in the ED Receive to result Koehler et al. Adv Emerg Nurs J. 2013; 35(3):270 277 Continuous Monitoring of Test TAT Performance Electronic laboratory information systems (LIS) and electronic medical records (EMR) facilitate data capture o Examples: Time of patient registration (arrival), order, collection, receipt, result, etc. TAT distribution is often non-guassian in nature o Non-parametric statistical analysis (i.e. Median and percentiles) Frequency Turnaround Time Steindel et al. Arch Pathol Lab Med, 2001. 125: 863 871. Continuous Monitoring of Test TAT Performance TAT is a key performance indicator of laboratory services 9

Continuous Monitoring of Test TAT Outliers Rate 2004 CAP Q tracks N = 175 Institutions TAT = Received to report Test outlier rates may serve as proxies for physician (dis)satisfaction o Assumption: If reporting goals are established by both the lab and providers that use lab services, then clinicians will be satisfied when the TAT goals are met and dissatisfied when TAT goals are not met Novis et al. Arch Pathol Lab Med. 2004;128:621 626 Test TAT Outlier Root Cause Analysis Proactive monitoring of quality indicator data and risk analysis of nonconforming events (e.g. TAT outliers) may identify common causal factor(s) potential continuous quality improvement opportunities 2014 CLSI QMS11 Nonconforming Event Management Chauhan et al. Ind J Clin Biochem. 2014; 29(4):505 509 Summary Important to understand the clinical needs and test TAT requirements for patient management decisions Test TAT, TAT outlier rates, and physician satisfaction survey results are key indicators of laboratory quality Laboratory test TAT definitions, goals and approaches to achieving timely testing depend on the institution and operational processes 10

Assessment Question Comprehensive Stroke Center certification requires documentation indicating the ability to achieve order to report lab test turnaround time within what timeframe? A. < 30 minutes B. < 45 minutes C. < 60 minutes D. < 90 minutes Assessment Question Lab test turnaround time is best defined as: A. Order to report B. Collect to report C. Receive to report D. Definition is institution-dependent Assessment Question Which strategy may be used for achieving timely testing for the Emergency Department? A. STAT testing performed in the central lab B. STAT testing performed in a satellite lab in the ED C. Point of Care Testing D. All of the above 11

Assessment Question Which of the following specimen types may cause prolonged delay in preanalytical specimen processing? A. Whole blood B. Plasma C. Serum with silica activator D. Serum with thrombin activator 12